D016271Chemicals & DrugsD12.776.260.103.813D12.776.624.664.700.189D12.776.660.765D12.776.930.125.813721200.923641Proto-Oncogene Proteins c-mycprns:emailEncryptedemail addressFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonRaymondMoelleringxW9mDq0ZHP7Qn31EdUXm+mb7+MTz7LFLRaymond E Moellering41.7886000000000087.598699999999993499Moellering, RaymondAssociate ProfessorMedicine-Rheumatology30252929Riedell PA, Smith SMCancerDouble hit and double expressors in lymphoma: Definition and treatment. Cancer. 2018 12 15; 124(24):4622-4632.Cancer2018-09-25T00:00:002018Double hit and double expressors in lymphoma: Definition and treatment.30707764Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SMCancerPhase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. Cancer. 2019 06 01; 125(11):1830-1836.Cancer2019-02-01T00:00:002019Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.31866228Miller AJ, Chang A, Cunningham PNAmerican journal of kidney diseases : the official journal of the National Kidney FoundationChronic Microangiopathy Due to DCR-MYC, a Myc-Targeted Short Interfering RNA. Am J Kidney Dis. 2020 04; 75(4):513-516.Am J Kidney Dis2019-12-19T00:00:002019Chronic Microangiopathy Due to DCR-MYC, a Myc-Targeted Short Interfering RNA.32101699Qiu Z, Lin AP, Jiang S, Elkashef SM, Myers J, Srikantan S, Sasi B, Cao JZ, Godley LA, Rakheja D, Lyu Y, Zheng S, Madesh M, Shiio Y, Dahia PLM, Aguiar RCTCell chemical biologyMYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome. Cell Chem Biol. 2020 05 21; 27(5):538-550.e7.Cell Chem Biol2020-02-25T00:00:002020MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome.Medicine-Hematology and Oncology1.233250.018033672research area of0.9063750.023029398subject area for36302987Speltz TE, Qiao Z, Swenson CS, Shangguan X, Coukos JS, Lee CW, Thomas DM, Santana J, Fanning SW, Greene GL, Moellering RENature biotechnologyTargeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains. Nat Biotechnol. 2023 04; 41(4):541-551.Nat Biotechnol2022-10-27T00:00:002022Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains.https://cgh.uchicago.edu/page/leadershipGlobal Healthhttps://www.uchicagomedicine.org/find-a-physician/physician/olufunmilayo-i-olopadeUChicago Medicinehttps://cancerbio.uchicago.edu/program/faculty/olufunmilayo-olopadeCancer Biologyhttps://www.uchicagomedicine.org/conditions-services/cancer/cancer-risk-preventionCancer Risk and Preventionhttps://voices.uchicago.edu/gounarilab/Gounari Lab SiteJamesDolezalJames Dolezal41.7886000000000087.598699999999994332Dolezal, JamesInstructorChemistryUniversity of ChicagoLucyGodley22VmD60QeczMknJtY0fp/Cv/+94=Lucy Godley41.78927490000000-87.601250000000001017Godley, LucyProfessorFotiniGounariFotini Gounari41.78927490000000-87.60125000000000138Gounari, FotiniAssociate ProfessorOlufunmilayoOlopade321vBIF1GuTQkntjbwjr93A=Olufunmilayo Olopade41.78927490000000-87.601250000000001960Olopade, OlufunmilayoProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1InstructorInstructortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor1010